RBC Capital raised the firm’s price target on MeiraGTx (MGTX) to $13 from $11 and keeps an Outperform rating on the shares after its Q4 results. The company is very pleased with the terms of the deal announced with private AI company Hologen and notes that the process was competitive, the analyst tells investors in a research note. MeiraGTx is also planning to submit an MAA with UK regulators based on its LCA4 results with no need for additional studies, and is in discussions with FDA on a path forward, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGTX:
- MeiraGTx price target raised to $14 from $12 at BofA
- MeiraGTx Holdings Faces Financial Uncertainty Over Priority Review Vouchers for Gene Therapy
- MeiraGTx Holdings Announces Joint Venture with Hologen
- MeiraGTx reports FY24 EPS ($2.12) vs ($1.49) last year
- MeiraGTx enters strategic collaboration with Hologen AI